<!DOCTYPE html>



<html lang="en">



	<meta charset="UTF-8">

	<meta name="viewport" content="width=device-width, initial-scale=1.0">

	<style>


    .node {

        stroke: #fff;

        stroke-width: 2px;

    }

    

    .link {

        stroke: #777;

        stroke-width: 2px;

    }



</style>

<body>

<a href="https://riskrunners.com">Home</a><br>




<a href="#risk_factors">Jump to Risk Factors</a><br>



<a href="#industry">Jump to Industries</a><br>


<a href="#exposure">Jump to Exposures</a><br>


<a href="#event_code">Jump to Event Codes</a><br>


<a href="#wiki">Jump to Wiki Summary</a><br><br>


    <script src="https://d3js.org/d3.v3.min.js"></script>

    <script>


// set a width and height for our SVG

var width = 3000,


    height = 3000;

    
// setup links

var links =     [
{source: "START_HERE", target: "4: relationships", fill: "#ffdb58"},
{source: "4: relationships", target: "4: distributors", fill: "#ffdb58"},
{source: "4: relationships", target: "10: healthcare industry", fill: "#f0f"},
{source: "10: healthcare industry", target: "10: highly regulated", fill: "#f0f"},
{source: "10: highly regulated", target: "10: regulatory influences", fill: "#f0f"},
{source: "10: healthcare industry", target: "11: recent years", fill: "#126180"},
{source: "11: recent years", target: "11: undergone significant", fill: "#126180"},
{source: "11: undergone significant", target: "11: driven by various", fill: "#126180"},
{source: "11: driven by various", target: "11: reduce costs", fill: "#126180"},
{source: "11: reduce costs", target: "11: spending budgets by", fill: "#126180"},
{source: "11: spending budgets by", target: "11: government", fill: "#126180"},
{source: "11: government", target: "11: private insurance programs such as", fill: "#126180"},
{source: "11: private insurance programs such as", target: "11: Medicare Medicaid ", fill: "#126180"},
{source: "11: Medicare Medicaid ", target: "11: consolidation", fill: "#126180"},
{source: "11: consolidation", target: "11: distribution", fill: "#126180"},
{source: "11: distribution", target: "11: collective", fill: "#126180"},
{source: "11: collective", target: "11: arrangements", fill: "#126180"},
{source: "11: arrangements", target: "11: practitioners", fill: "#126180"},
{source: "11: practitioners", target: "11: reimbursements", fill: "#126180"},
{source: "11: recent years", target: "14: must comply with government regulations governing", fill: "#4b3621"},
{source: "14: must comply with government regulations governing", target: "14: distribution", fill: "#4b3621"},
{source: "14: distribution", target: "14: pharmaceuticals", fill: "#4b3621"},
{source: "14: pharmaceuticals", target: "14: medical devices", fill: "#4b3621"},
{source: "14: medical devices", target: "14: additional regulations could", fill: "#4b3621"},
{source: "14: additional regulations could", target: "14: negatively affect", fill: "#4b3621"},
{source: "14: must comply with government regulations governing", target: "19: requirements", fill: "#c08081"},
{source: "19: requirements", target: "19: foreign governmental laws", fill: "#c08081"},
{source: "19: foreign governmental laws", target: "19: regulations", fill: "#c08081"},
{source: "19: regulations", target: "19: affecting", fill: "#c08081"},
{source: "19: affecting", target: "19: operations abroad", fill: "#c08081"},
{source: "19: requirements", target: "27: comply with laws", fill: "#5d8aa8"},
{source: "27: comply with laws", target: "27: regulations", fill: "#5d8aa8"},
{source: "27: regulations", target: "27: could suffer penalties", fill: "#5d8aa8"},
{source: "27: could suffer penalties", target: "27: significant", fill: "#5d8aa8"},
{source: "27: significant", target: "27: operations", fill: "#5d8aa8"},
{source: "27: comply with laws", target: "37: acquisition", fill: "#bf4f51"},
{source: "37: acquisition", target: "37: of the Demedis Group ", fill: "#bf4f51"},
{source: "37: of the Demedis Group ", target: "37: foreign operations", fill: "#bf4f51"},
{source: "37: foreign operations", target: "37: significantly larger", fill: "#bf4f51"},
{source: "37: significantly larger", target: "37: risks inherent", fill: "#bf4f51"},
{source: "37: risks inherent", target: "37: international operations", fill: "#bf4f51"},
{source: "37: acquisition", target: "45: meet market expectations", fill: "#fffff0"},
{source: "45: meet market expectations", target: "45: stock price may decline", fill: "#fffff0"},
{source: "45: meet market expectations", target: "53: interruption", fill: "#c3b091"},
{source: "53: interruption", target: "53: influenza vaccine", fill: "#c3b091"},
{source: "53: influenza vaccine", target: "53: high sales volume product would", fill: "#c3b091"},
{source: "53: high sales volume product would", target: "53: Contents ", fill: "#c3b091"},
{source: "53: Contents ", target: "53: operations which most likely would", fill: "#c3b091"},
{source: "53: operations which most likely would", target: "53: adversely affect", fill: "#c3b091"},
{source: "53: adversely affect", target: "53: common stock", fill: "#c3b091"},
{source: "53: interruption", target: "54: expansion through acquisitions", fill: "#3c341f"},
{source: "54: expansion through acquisitions", target: "54: joint ventures involves risks", fill: "#3c341f"},
{source: "54: expansion through acquisitions", target: "56: transactions", fill: "#e1ad21"},
{source: "56: transactions", target: "56: involve numerous risks", fill: "#e1ad21"},
{source: "56: involve numerous risks", target: "56: possible adverse effects on", fill: "#e1ad21"},
{source: "56: possible adverse effects on", target: "56: market price", fill: "#e1ad21"},
{source: "56: market price", target: "56: common stock", fill: "#e1ad21"},
{source: "56: transactions", target: "START_HERE", fill: "#e1ad21"}]; 
    // create empty nodes array
    var nodes = {};
	var colorFill = [];
	
    // compute nodes from links data
    links.forEach(function(link) {
        link.source = nodes[link.source] ||
            (nodes[link.source] = {name: link.source});
        link.target = nodes[link.target] ||
            (nodes[link.target] = {name: link.target});
		colorFill.push({name: link.source.name, fill: link.fill });
		colorFill.push({name: link.target.name, fill: link.fill });
    });
	
	console.log(colorFill);


    // add a SVG to the body for our viz
    var svg=d3.select('body').append('svg')
        .attr("viewBox", "0 0 " + width + " " + height );

    // use the force
    var force = d3.layout.force()
		.charge(-5000)
		.gravity(0.3)
        .size([width, height])
        .nodes(d3.values(nodes))
        .links(links)
        .on("tick", tick)
        .linkDistance(200)
        .start();

    // add links
    var link = svg.selectAll('.link')
        .data(links)
        .enter().append('line')
        .attr('class', 'link'); 

    // add nodes
    var node = svg.selectAll('.node')
        .data(force.nodes())
        .enter().append('circle')
        .attr('class', 'node')
        .attr('r', width * 0.0035)
		.style("fill", function(d) {
									for (var i = 0; i < colorFill.length; i++) {
										//console.log(d.name);
										if(colorFill[i].name == d.name){
											console.log(colorFill[i].fill);
											return colorFill[i].fill;
										}
									} return "#555";
									
									});
	var label = svg.selectAll(null)
		.data(force.nodes())
		.enter()
		.append("text")
		.text(function (d) { return d.name; })
		.style("text-anchor", "middle")
		.style("fill", "#555")
		.style("font-family", "Arial")
		.style("font-size", 34);


    // what to do 
    function tick(e) {
        
        node.attr('cx', function(d) { return d.x = Math.max(6, Math.min(width - 6, d.x)); })
            .attr('cy', function(d) { return d.y = Math.max(6, Math.min(height - 6, d.y)); })
            .call(force.drag);
            
        link.attr('x1', function(d) { return d.source.x; })
            .attr('y1', function(d) { return d.source.y; })
            .attr('x2', function(d) { return d.target.x; })
            .attr('y2', function(d) { return d.target.y; });
		
		label.attr("x", function(d){ return d.x; })
             .attr("y", function (d) {return d.y - 10; });
        
    }
    
</script><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='industry'>Industries</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>Automobile Manufacturers</td>
    </tr>
    <tr>
      <td>Motorcycle Manufacturers</td>
    </tr>
    <tr>
      <td>Food Distributors</td>
    </tr>
    <tr>
      <td>Trading Companies and Distributors</td>
    </tr>
    <tr>
      <td>Health Care Distribution and Services</td>
    </tr>
    <tr>
      <td>Pharmaceuticals Biotechnology and Life Sciences</td>
    </tr>
    <tr>
      <td>Pharmaceuticals</td>
    </tr>
    <tr>
      <td>Advertising</td>
    </tr>
    <tr>
      <td>Oil and Gas Storage and Transportation</td>
    </tr>
    <tr>
      <td>Oil and Gas Refining and Marketing and Transportation</td>
    </tr>
    <tr>
      <td>Transportation</td>
    </tr>
    <tr>
      <td>Technology Hardware Storage and Peripherals</td>
    </tr>
    <tr>
      <td>Information Technology</td>
    </tr>
    <tr>
      <td>Technology Hardware and Equipment</td>
    </tr>
    <tr>
      <td>Asset Management and Custody Banks</td>
    </tr>
  </tbody>
</table><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='exposure'>Exposures</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>Regime</td>
    </tr>
    <tr>
      <td>Cooperate</td>
    </tr>
    <tr>
      <td>Military</td>
    </tr>
    <tr>
      <td>Express intent</td>
    </tr>
    <tr>
      <td>Leadership</td>
    </tr>
    <tr>
      <td>Provide</td>
    </tr>
    <tr>
      <td>Rights</td>
    </tr>
    <tr>
      <td>Intelligence</td>
    </tr>
    <tr>
      <td>Judicial</td>
    </tr>
  </tbody>
</table><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='event_code'>Event Codes</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>Agree</td>
    </tr>
    <tr>
      <td>Host meeting</td>
    </tr>
    <tr>
      <td>Sanction</td>
    </tr>
    <tr>
      <td>Travel to meet</td>
    </tr>
    <tr>
      <td>Reject</td>
    </tr>
    <tr>
      <td>Vote</td>
    </tr>
    <tr>
      <td>Warn</td>
    </tr>
    <tr>
      <td>Solicit support</td>
    </tr>
    <tr>
      <td>Reduce routine activity</td>
    </tr>
    <tr>
      <td>Reward</td>
    </tr>
    <tr>
      <td>Yield to order</td>
    </tr>
    <tr>
      <td>Yield</td>
    </tr>
    <tr>
      <td>Release or return</td>
    </tr>
    <tr>
      <td>Accuse</td>
    </tr>
    <tr>
      <td>Sports contest</td>
    </tr>
    <tr>
      <td>Force</td>
    </tr>
    <tr>
      <td>Defy norms</td>
    </tr>
    <tr>
      <td>Acknowledge responsibility</td>
    </tr>
    <tr>
      <td>Promise</td>
    </tr>
    <tr>
      <td>Human death</td>
    </tr>
    <tr>
      <td>Demand</td>
    </tr>
  </tbody>
</table><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='wiki'>Wiki</th>
      <th>Wiki Summary</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Customer_relationship_management">Customer relationship management</a></td>
      <td>Customer relationship management (CRM) is a process in which a business or other organization administers its interactions with customers, typically using data analysis to study large amounts of information.CRM systems compile data from a range of different communication channels, including a company's website, telephone, email, live chat, marketing materials and more recently, social media. They allow businesses to learn more about their target audiences and how to best cater for their needs, thus retaining customers and driving sales growth.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Regulation">Regulation</a></td>
      <td>Regulation is the management of complex systems according to a set of rules and trends. In systems theory, these types of rules exist in various fields of biology and society, but the term has slightly different meanings according to context.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Normal_distribution">Normal distribution</a></td>
      <td>In statistics, a normal distribution (also known as Gaussian, Gauss, or Laplace–Gauss distribution) is a type of continuous probability distribution for a real-valued random variable. The general form of its probability density function is\n\n  \n    \n      \n        f\n        (\n        x\n        )\n        =\n        \n          \n            1\n            \n              σ\n              \n                \n                  2\n                  π\n                \n              \n            \n          \n        \n        \n          e\n          \n            −\n            \n              \n                1\n                2\n              \n            \n            \n              \n                (\n                \n                  \n                    \n                      x\n                      −\n                      μ\n                    \n                    σ\n                  \n                \n                )\n              \n              \n                2\n              \n            \n          \n        \n      \n    \n    {\displaystyle f(x)={\frac {1}{\sigma {\sqrt {2\pi }}}}e^{-{\frac {1}{2}}\left({\frac {x-\mu }{\sigma }}\right)^{2}}}\n  The parameter \n  \n    \n      \n        μ\n      \n    \n    {\displaystyle \mu }\n   is the mean or expectation of the distribution (and also its median and mode), while the parameter \n  \n    \n      \n        σ\n      \n    \n    {\displaystyle \sigma }\n   is its standard deviation.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Exponential_distribution">Exponential distribution</a></td>
      <td>In probability theory and statistics, the exponential distribution is the probability distribution of the time between events in a Poisson point process, i.e., a process in which events occur continuously and independently at a constant average rate. It is a particular case of the gamma distribution.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Gamma_distribution">Gamma distribution</a></td>
      <td>In probability theory and statistics, the gamma distribution is a two-parameter family of continuous probability distributions.  The exponential distribution, Erlang distribution, and chi-square distribution are special cases of the gamma distribution.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Binomial_distribution">Binomial distribution</a></td>
      <td>In probability theory and statistics, the binomial distribution with parameters n and p is the discrete probability distribution of the number of successes in a sequence of n independent experiments, each asking a yes–no question, and each with its own Boolean-valued outcome: success (with probability p) or failure (with probability q = 1 − p). A single success/failure experiment is also called a Bernoulli trial or Bernoulli experiment, and a sequence of outcomes is called a Bernoulli process; for a single trial, i.e., n = 1, the binomial distribution is a Bernoulli distribution.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Film_distribution">Film distribution</a></td>
      <td>Film distribution is the process of making a movie available for viewing by an audience. This is normally the task of a professional film distributor, who would determine the marketing strategy for the film, the media by which a film is to be exhibited or made available for viewing, and who may set the release date and other matters.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Beta_distribution">Beta distribution</a></td>
      <td>In probability theory and statistics, the beta distribution is a family of continuous probability distributions defined on the interval [0, 1] parameterized by two positive shape parameters, denoted by alpha (α) and beta (β), that appear as exponents of the random variable and control the shape of the distribution. The generalization to multiple variables is called a Dirichlet distribution.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Pareto_distribution">Pareto distribution</a></td>
      <td>The Pareto distribution, named after the Italian civil engineer, economist, and sociologist Vilfredo Pareto, (Italian: [paˈreːto] US:  pə-RAY-toh), is a power-law probability distribution that is used in description of social, quality control, scientific, geophysical, actuarial, and many other types of observable phenomena. Originally applied to describing the distribution of wealth in a society, fitting the trend that a large portion of wealth is held by a small fraction of the population.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Cauchy_distribution">Cauchy distribution</a></td>
      <td>The Cauchy distribution, named after Augustin Cauchy, is a continuous probability distribution.  It is also known, especially among physicists, as the Lorentz distribution (after Hendrik Lorentz), Cauchy–Lorentz distribution, Lorentz(ian) function, or Breit–Wigner distribution.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Regulation_of_therapeutic_goods">Regulation of therapeutic goods</a></td>
      <td>The regulation of therapeutic goods, defined as drugs and therapeutic devices, varies by jurisdiction. In some countries, such as the United States, they are regulated at the national level by a single agency.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Formula_One_regulations">Formula One regulations</a></td>
      <td>The numerous Formula One regulations, made and enforced by the FIA and later the FISA, have changed dramatically since the first Formula One World Championship in 1950. This article covers the current state of F1 technical and sporting regulations, as well as the history of the technical regulations since 1950.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Regulation_A">Regulation A</a></td>
      <td>In the United States under the Securities Act of 1933, any offer to sell securities must either be registered with the United States Securities and Exchange Commission (SEC) or meet certain qualifications to exempt it from such registration. Regulation A (or Reg A) contains rules providing exemptions from the registration requirements, allowing some companies to use equity crowdfunding to offer and sell their securities without having to register the securities with the SEC. Regulation A offerings are intended to make access to capital possible for small and medium-sized companies that could not otherwise bear the costs of a normal SEC registration and to allow nonaccredited investors to participate in the offering.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Regulation_(European_Union)">Regulation (European Union)</a></td>
      <td>A regulation is a legal act of the European Union that becomes immediately enforceable as law in all member states simultaneously. Regulations can be distinguished from directives which, at least in principle, need to be transposed into national law.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/New_York_Codes,_Rules_and_Regulations">New York Codes, Rules and Regulations</a></td>
      <td>The New York Codes, Rules and Regulations (NYCRR) contains New York state rules and regulations. The NYCRR is officially compiled by the New York State Department of State's Division of Administrative Rules.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Allosteric_regulation">Allosteric regulation</a></td>
      <td>In biochemistry, allosteric regulation (or allosteric control) is the regulation of an enzyme by binding an effector molecule at a site other than the enzyme's active site.The site to which the effector binds is termed the allosteric site or regulatory site. Allosteric sites allow effectors to bind to the protein, often resulting in a conformational change involving protein dynamics.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Arithmetic">Arithmetic</a></td>
      <td>Arithmetic (from Ancient Greek  ἀριθμός (arithmós) 'number', and  τική [τέχνη] (tikḗ [tékhnē]) 'art, craft') is an elementary part of mathematics that consists of the study of the properties of the traditional operations on numbers—addition, subtraction, multiplication, division, exponentiation, and extraction of roots. In the 19th century, Italian mathematician Giuseppe Peano formalized arithmetic with his Peano axioms, which are highly important to the field of mathematical logic today.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Operation_Mincemeat">Operation Mincemeat</a></td>
      <td>Operation Mincemeat was a successful British deception operation of the Second World War to disguise the 1943 Allied invasion of Sicily. Two members of British intelligence obtained the body of Glyndwr Michael, a tramp who died from eating rat poison, dressed him as an officer of the Royal Marines and placed personal items on him identifying him as the fictitious Captain (Acting Major) William Martin.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Special_Activities_Center">Special Activities Center</a></td>
      <td>The Special Activities Center (SAC) is a division of the Central Intelligence Agency responsible for covert operations and paramilitary operations. The unit was named Special Activities Division (SAD) prior to 2015.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Operations_management">Operations management</a></td>
      <td>Operations management is an area of management concerned with designing and controlling the process of production and redesigning business operations in the production of goods or services. It involves the responsibility of ensuring that business operations are efficient in terms of using as few resources as needed and effective in meeting customer requirements.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Operations_research">Operations research</a></td>
      <td>Operations research (British English: operational research), often shortened to the initialism OR, is a discipline that deals with the development and application of advanced analytical methods to improve decision-making. It is sometimes considered to be a subfield of mathematical sciences.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Surgery">Surgery</a></td>
      <td>Surgery is a medical or dental specialty that uses operative manual and instrumental techniques on a person to investigate or treat a pathological condition such as a disease or injury, to help improve bodily function, appearance, or to repair unwanted ruptured areas.\nThe act of performing surgery may be called a surgical procedure, operation, or simply "surgery".</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Bitwise_operation">Bitwise operation</a></td>
      <td>In computer programming, a bitwise operation operates on a bit string, a bit array or a binary numeral (considered as a bit string) at the level of its individual bits. It is a fast and simple action, basic to the higher-level arithmetic operations and directly supported by the processor.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Mergers_and_acquisitions">Mergers and acquisitions</a></td>
      <td>In corporate finance, mergers and acquisitions (M&amp;A) are transactions in which the ownership of companies, other business organizations, or their operating units are transferred or consolidated with other entities. As an aspect of strategic management, M&amp;A can allow enterprises to grow or downsize, and change the nature of their business or competitive position.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Market_trend">Market trend</a></td>
      <td>A market trend is a perceived tendency of financial markets to move in a particular direction over time. These trends are classified as secular for long time frames, primary for medium time frames, and secondary for short time frames.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Pricing_strategies">Pricing strategies</a></td>
      <td>A business can use a variety of pricing strategies when selling a product or service. To determine the most effective pricing strategy for a company, senior executives need to first identify the company's pricing position, pricing segment, pricing capability and their competitive pricing reaction strategy.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Non-price_competition">Non-price competition</a></td>
      <td>Non-price competition is a marketing strategy "in which one firm tries to distinguish its product or service from competing products on the basis of attributes like design and workmanship". It often occurs in imperfectly competitive markets because it exists between two or more producers that sell goods and services at the same prices but compete to increase their respective market shares through non-price measures such as marketing schemes and greater quality.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Price">Price</a></td>
      <td>A prince is a male ruler (ranked below a king, grand prince, and grand duke) or a male member of a monarch's or former monarch's family. Prince is also a title of nobility (often highest), often hereditary, in some European states.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Market_power">Market power</a></td>
      <td>In economics, market power refers to the ability of a firm to influence the price at which it sells a product or service by manipulating either the supply or demand of the product or service to increase economic profit. In other words, market power occurs if a firm does not face a perfectly elastic demand curve and can set its price (P) above marginal cost (MC) without losing revenue.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Price_discrimination">Price discrimination</a></td>
      <td>Price discrimination is a microeconomic pricing strategy where identical or largely similar goods or services are sold at different prices by the same provider in different markets. Price discrimination is distinguished from product differentiation by the more substantial difference in production cost for the differently priced products involved in the latter strategy.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Price_Chopper_and_Market_32_Supermarkets">Price Chopper and Market 32 Supermarkets</a></td>
      <td>Golub Corporation is an American supermarket operator. Headquartered in Schenectady, New York, it owns the chains Market 32 and Price Chopper Supermarkets.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Pricing">Pricing</a></td>
      <td>Pricing is the process whereby a business sets the price at which it will sell its products and services, and may be part of the business's marketing plan. In setting prices, the business will take into account the price at which it could acquire the goods, the manufacturing cost, the marketplace, competition, market condition, brand, and quality of product.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Volatility_(finance)">Volatility (finance)</a></td>
      <td>In finance, volatility (usually denoted by σ) is the degree of variation of a trading price series over time, usually measured by the standard deviation of logarithmic returns.\nHistoric volatility measures a time series of past market prices.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Market_structure">Market structure</a></td>
      <td>Market structure, in economics, depicts how firms are differentiated and categorised based on the types of goods they sell (homogeneous/heterogeneous) and how their operations are affected by external factors and elements. Market structure makes it easier to understand the characteristics of diverse markets.</td>
    </tr>
  </tbody>
</table><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='risk_factors'>Risk Factors</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>SCHEIN HENRY INC      ITEM 1A Risk Factors     The <font color="blue"><font color="blue">healthcare products</font> <font color="blue">distribution</font> industry</font> is <font color="blue">highly <font color="blue">competitive</font></font>, and we     may not be able to <font color="blue">compete <font color="blue">successfully</font></font></td>
    </tr>
    <tr>
      <td>We  compete  with  numerous  companies,  including  <font color="blue">several major</font>     <font color="blue"><font color="blue"><font color="blue">manufacture</font>r</font>s</font>  and  <font color="blue">distributors</font></td>
    </tr>
    <tr>
      <td>Some of our <font color="blue">competitors</font> have greater     financial and other <font color="blue">resources than</font> we do, <font color="blue">which could allow them</font> to compete     more <font color="blue">successfully</font></td>
    </tr>
    <tr>
      <td>Most of our products are available from several sources     and our customers tend to have <font color="blue">relationships</font> with several <font color="blue">distributors</font></td>
    </tr>
    <tr>
      <td><font color="blue">Competitors </font>could obtain <font color="blue">exclusive rights</font> to market particular products,     which we would then be unable to market</td>
    </tr>
    <tr>
      <td><font color="blue">Manufacturers </font><font color="blue">could also increase</font>     their efforts to <font color="blue">sell directly</font> to end-users and bypass <font color="blue">distributors</font> like us</td>
    </tr>
    <tr>
      <td><font color="blue">Industry  </font><font color="blue">consolidation</font>  among  healthcare  products <font color="blue">distributors</font>, the     <font color="blue">un<font color="blue">availability</font></font> of products, whether due to our <font color="blue">inability</font> to <font color="blue">gain access</font> to     products or <font color="blue"><font color="blue">interruption</font>s</font> in supply from <font color="blue"><font color="blue"><font color="blue">manufacture</font>r</font>s</font>, or the emergence of     new <font color="blue">competitors</font> <font color="blue">could also increase</font> <font color="blue">competition</font></td>
    </tr>
    <tr>
      <td>In the future, we may be     unable to <font color="blue">compete <font color="blue">successfully</font></font> and <font color="blue">competitive</font> pressures may reduce our     revenues</td>
    </tr>
    <tr>
      <td>The <font color="blue">healthcare industry</font> is experiencing changes that <font color="blue">could <font color="blue">adversely</font> affect</font>     our business</td>
    </tr>
    <tr>
      <td>The <font color="blue">healthcare industry</font> is <font color="blue">highly regulated</font> and subject to changing     political,  economic  and  <font color="blue">regulatory influences</font></td>
    </tr>
    <tr>
      <td>In <font color="blue">recent years</font>, the     <font color="blue">healthcare industry</font> has <font color="blue">undergone <font color="blue">significant</font></font> change <font color="blue">driven by various</font>     efforts to <font color="blue">reduce costs</font>, including the reduction of <font color="blue">spending budgets by</font>     <font color="blue">government</font> and private insurance programs, such as Medicare, Medicaid and     corporate health insurance plans; pressures relating to potential healthcare     reform; trends toward managed care; <font color="blue">consolidation</font> of healthcare <font color="blue">distribution</font>     companies; <font color="blue">collective</font> purchasing <font color="blue">arrangements</font> among office-based healthcare     <font color="blue">practitioners</font>; and changes in <font color="blue">reimbursements</font> to customers</td>
    </tr>
    <tr>
      <td>If we are unable     to <font color="blue">react <font color="blue">effectively</font></font> to these and other changes in the <font color="blue">healthcare industry</font>,     our  operating  results  could be <font color="blue"><font color="blue">adversely</font> affected</font></td>
    </tr>
    <tr>
      <td>In addition, the     <font color="blue">enactment</font>  of any <font color="blue"><font color="blue">significant</font> healthcare reforms could</font> have a material     adverse effect on our business</td>
    </tr>
    <tr>
      <td>We must <font color="blue">comply with</font> <font color="blue">government</font> <font color="blue">regulations</font> governing the <font color="blue">distribution</font> of     <font color="blue"><font color="blue">pharmaceutical</font>s</font>  and <font color="blue">medical devices</font>, and <font color="blue">additional <font color="blue">regulations</font> could</font>     <font color="blue">negatively affect</font> our business</td>
    </tr>
    <tr>
      <td>Our business is subject to <font color="blue"><font color="blue">requirements</font> under various local</font>, state,     federal and international <font color="blue">government</font>al laws and <font color="blue"><font color="blue">regulations</font> applicable</font> to     the <font color="blue">distribution</font> of <font color="blue"><font color="blue">pharmaceutical</font>s</font> and <font color="blue">medical devices</font></td>
    </tr>
    <tr>
      <td>Among the federal     laws  with which we must comply are the Controlled Substances Act, the     Federal Food, Drug, and Cosmetic Act, as amended, the Prescription Drug     Marketing Act of 1987 <font color="blue">and the Safe Medical Devices Act </font>of 1990, as amended</td>
    </tr>
    <tr>
      <td>Such laws:     •   regulate the storage and <font color="blue">distribution</font>, labeling, handling, record     keeping, <font color="blue">manufacturing</font> and <font color="blue">advertising</font> of drugs and <font color="blue">medical devices</font>;     •   subject us to inspection by the <font color="blue">Federal Food and Drug Administration </font>and     the Drug Enforcement Administration;     •   regulate the <font color="blue">transportation</font> of certain of our products that are     considered <font color="blue">hazardous materials</font>;     •   require <font color="blue">registration with</font> the <font color="blue">Federal Food and Drug Administration </font>and     the Drug Enforcement Administration;     •   require us to <font color="blue">coordinate returns</font> of products that have <font color="blue">been recalled</font> and     subject us to inspection of our <font color="blue">recall procedures</font>; and     •   impose reporting <font color="blue">requirements</font> if a <font color="blue">pharmaceutical</font> or medical device     causes serious illness, injury or death</td>
    </tr>
    <tr>
      <td>14       _________________________________________________________________    [68]Table of <font color="blue"><font color="blue">Contents       </font>   </font>  Applicable federal and state laws and <font color="blue"><font color="blue">regulations</font> may also</font> require us     to <font color="blue">meet various standards</font> relating to, among other things, licensure or     registration, sales and marketing practices, product supply tracking to the     <font color="blue"><font color="blue">manufacture</font>r</font> of the product, personnel, privacy of health or other personal     information, and the <font color="blue">importation</font> and <font color="blue">exportation</font> of products</td>
    </tr>
    <tr>
      <td>Our business     is also subject to <font color="blue">requirements</font> of foreign <font color="blue">government</font>al laws and <font color="blue">regulations</font>     <font color="blue">affecting</font> our <font color="blue"><font color="blue">operations</font> abroad</font></td>
    </tr>
    <tr>
      <td>The  failure  to  comply  with  any  of these <font color="blue">regulations</font>, or new     <font color="blue">interpretations</font> of <font color="blue">existing laws</font> and <font color="blue">regulations</font>, or the imposition of any     <font color="blue">additional laws</font> and <font color="blue">regulations</font> could <font color="blue">negatively affect</font> our business</td>
    </tr>
    <tr>
      <td><font color="blue">There     </font>can  be  no  assurance that current or future <font color="blue">United States </font>or foreign     <font color="blue">government</font> <font color="blue">regulations</font> will not <font color="blue">adversely</font> affect our business</td>
    </tr>
    <tr>
      <td>The costs to     <font color="blue">us associated with complying with</font> the <font color="blue">various applicable federal</font> and state     statutes and <font color="blue">regulations</font>, as they now exist and as they may be modified,     could be material</td>
    </tr>
    <tr>
      <td><font color="blue">Allegations </font>by a state or the federal <font color="blue">government</font> that we     have not <font color="blue">complied with</font> these laws could have a material <font color="blue">adverse impact on</font>     our <font color="blue">businesses</font></td>
    </tr>
    <tr>
      <td>If it is determined that we have not <font color="blue">complied with</font> these     laws, or if we <font color="blue">enter into settlement <font color="blue">agreements</font></font> to <font color="blue">resolve allegations</font> of     non-compliance, we could be required to make <font color="blue">settlement payments</font> or be     subject to civil and <font color="blue">criminal penalties</font>, including fines and the loss of     licenses or our ability to <font color="blue">participate</font> in federal and state healthcare     programs</td>
    </tr>
    <tr>
      <td>Any of the <font color="blue">foregoing could</font> have a material <font color="blue">adverse impact on</font> our     <font color="blue">businesses</font></td>
    </tr>
    <tr>
      <td>We believe that the <font color="blue">healthcare services industry will continue</font>     to be subject to extensive <font color="blue">regulation at</font> the federal, state, and local     levels and that we have <font color="blue">adequate compliance programs</font> and controls to ensure     <font color="blue">compliance with</font> the laws and <font color="blue">regulations</font></td>
    </tr>
    <tr>
      <td>If we fail to <font color="blue"><font color="blue">comply with</font> laws</font> and <font color="blue">regulations</font> in respect of healthcare     fraud, we <font color="blue">could suffer penalties</font> or be required to make <font color="blue">significant</font> changes     to our <font color="blue">operations</font></td>
    </tr>
    <tr>
      <td>We are subject to extensive and <font color="blue">frequently</font> changing federal and state     laws and <font color="blue">regulations</font> relating to <font color="blue">healthcare fraud</font></td>
    </tr>
    <tr>
      <td>The federal <font color="blue">government</font>     continues to strengthen its position and <font color="blue">scrutiny over practices involving</font>     <font color="blue">healthcare fraud</font> <font color="blue">affecting</font> <font color="blue">government</font> <font color="blue">healthcare programs</font></td>
    </tr>
    <tr>
      <td>Our <font color="blue">relationships</font>     with <font color="blue">pharmaceutical</font> <font color="blue"><font color="blue"><font color="blue">manufacture</font>r</font>s</font> and <font color="blue">healthcare providers</font> subject our     business to laws and <font color="blue">regulations</font> on fraud and abuse which, among other     things, (i) prohibit persons from soliciting, offering, receiving or paying     any <font color="blue">remuneration</font> in order to induce the referral of a patient for treatment     or for inducing the ordering or purchasing of items or services that are in     any way paid for by <font color="blue">government</font>-sponsored <font color="blue">healthcare programs</font> and (ii) impose     a  number  of  <font color="blue">restrictions upon referring physicians</font> and providers of     designated health services under <font color="blue">government</font> <font color="blue">healthcare programs</font></td>
    </tr>
    <tr>
      <td>While we     believe that we are <font color="blue"><font color="blue">substantially</font> compliant with</font> all <font color="blue">applicable laws</font>, many     of the <font color="blue"><font color="blue">regulations</font> applicable</font> to us are vague or <font color="blue">indefinite</font> and have not     <font color="blue">been interpreted by</font> the courts</td>
    </tr>
    <tr>
      <td>They may be interpreted or <font color="blue">applied by</font> a     prosecutorial, regulatory or <font color="blue">judicial authority</font> in a manner that could     require us to make changes in our <font color="blue">operations</font></td>
    </tr>
    <tr>
      <td>If we fail to <font color="blue">comply with</font>     applicable  laws  and  <font color="blue">regulations</font>, we <font color="blue">could suffer civil</font> and criminal     penalties, including the loss of licenses or our ability to <font color="blue">participate</font> in     federal and state <font color="blue">healthcare programs</font></td>
    </tr>
    <tr>
      <td>Our  international <font color="blue">operations</font> are subject to <font color="blue">inherent risks</font> that could     <font color="blue">adversely</font> affect our operating results</td>
    </tr>
    <tr>
      <td><font color="blue">International </font><font color="blue">operations</font> are subject to risks that <font color="blue">may materially</font>     <font color="blue">adversely</font>  affect  our  business,  results of <font color="blue">operations</font> and financial     condition</td>
    </tr>
    <tr>
      <td>The risks that our international <font color="blue">operations</font> are subject to     include:     •   <font color="blue"><font color="blue">difficult</font>ies</font> and costs relating to staffing and <font color="blue">managing foreign</font>     <font color="blue">operations</font>;     •   <font color="blue"><font color="blue">difficult</font>ies</font> in <font color="blue"><font color="blue">establishing</font> channels</font> of <font color="blue">distribution</font>;     •   <font color="blue">fluctuations</font> in the value of <font color="blue">foreign currencies</font>;     •   <font color="blue">longer payment cycles</font> of <font color="blue">foreign customers</font> and <font color="blue"><font color="blue">difficult</font>y</font> of collecting     <font color="blue">receivables</font> in <font color="blue">foreign jurisdictions</font>;     •   <font color="blue">repatriation</font> of cash from our foreign <font color="blue">operations</font> to the United States;     •   regulatory <font color="blue">requirements</font>;                                         15       _________________________________________________________________    [69]Table of <font color="blue">Contents       </font>•   unexpected <font color="blue"><font color="blue">difficult</font>ies</font> in importing or exporting our products;     •   imposition of import/export duties, quotas, sanctions or penalties; and     •   unexpected regulatory, economic and political changes in foreign     markets</td>
    </tr>
    <tr>
      <td>As a result of our <font color="blue">acquisition</font> <font color="blue">of the <font color="blue">Demedis Group </font></font>and other foreign     companies, our foreign <font color="blue">operations</font> are <font color="blue">significant</font>ly larger and, therefore,     our exposure to the <font color="blue">risks inherent</font> in international <font color="blue">operations</font> has become     greater</td>
    </tr>
    <tr>
      <td>We experience <font color="blue">fluctuations</font> in <font color="blue">quarterly earnings</font></td>
    </tr>
    <tr>
      <td>As a result, we may fail     to meet or exceed the <font color="blue">expectations</font> of securities analysts and investors,     which could cause our stock price to decline</td>
    </tr>
    <tr>
      <td>Our business is subject to seasonal and other quarterly <font color="blue">fluctuations</font></td>
    </tr>
    <tr>
      <td>Net sales and operating <font color="blue">profits generally</font> have <font color="blue">been higher</font> in the third and     <font color="blue">fourth quarters due</font> to the timing of sales of <font color="blue">seasonal products</font> (including     <font color="blue">influenza vaccine</font>, equipment and <font color="blue">software products</font>), purchasing patterns of     office-based healthcare <font color="blue">practitioners</font> and year-end promotions</td>
    </tr>
    <tr>
      <td>Net sales and     operating <font color="blue">profits generally</font> have <font color="blue">been lower</font> in the first quarter, primarily     due to <font color="blue">increased sales</font> in the <font color="blue">prior two quarters</font></td>
    </tr>
    <tr>
      <td><font color="blue">Quarterly </font>results may also     be <font color="blue"><font color="blue">adversely</font> affected</font> by a variety of other factors, including:     •   costs of developing <font color="blue">new applications</font> and services;     •   costs related to <font color="blue">acquisition</font>s and/or <font color="blue">integration</font>s of <font color="blue">technologies</font> or     <font color="blue">businesses</font>;     •   timing and amount of sales and <font color="blue">marketing expenditures</font>;     •   loss of <font color="blue">sales representatives</font>;     •   general <font color="blue">economic conditions</font>, as well as those specific to the healthcare     industry and related <font color="blue">industries</font>;     •   timing of the release of functions of our <font color="blue">technology</font>-related products     and services;     •   <font color="blue">establishing</font> or maintaining business <font color="blue">relationships</font>;     •   <font color="blue">consummating</font> the sale of our Hospital Supply Business;     •   changes in <font color="blue">accounting principles</font>; and     •   <font color="blue">product <font color="blue">availability</font></font> or recalls by <font color="blue"><font color="blue"><font color="blue">manufacture</font>r</font>s</font></td>
    </tr>
    <tr>
      <td>Any change in one or more of these or other <font color="blue">factors could</font> cause our     annual or quarterly operating results to fluctuate</td>
    </tr>
    <tr>
      <td>If our operating results     do not meet market <font color="blue">expectations</font>, our <font color="blue">stock price may decline</font></td>
    </tr>
    <tr>
      <td><font color="blue">Because  </font><font color="blue">substantially</font>  all of the products that we distribute are not     <font color="blue">manufacture</font>d by us, we are <font color="blue">dependent upon third parties</font> for the <font color="blue">manufacture</font>     and supply of <font color="blue">substantially</font> all of our products</td>
    </tr>
    <tr>
      <td>We obtain <font color="blue">substantially</font> all of our products from third-party suppliers</td>
    </tr>
    <tr>
      <td>Generally, we do not have long-term contracts with our <font color="blue">suppliers committing</font>     them to <font color="blue">supply products</font> to us</td>
    </tr>
    <tr>
      <td>Therefore, <font color="blue">suppliers may</font> not provide the     products we need in the quantities we request</td>
    </tr>
    <tr>
      <td>Because we do not control the     <font color="blue">actual production</font> of the products we sell, we may be subject to delays     caused <font color="blue">by <font color="blue">interruption</font></font> in <font color="blue">production based on conditions outside</font> of our     control</td>
    </tr>
    <tr>
      <td>In the event that any of our third-party suppliers were to become     unable or unwilling to continue to provide the products in required volumes,     we would need to identify and obtain acceptable <font color="blue">replacement sources on</font> a     <font color="blue">timely basis</font></td>
    </tr>
    <tr>
      <td>There is no guarantee that we will be able to obtain such     <font color="blue">alternative sources</font> of supply on a <font color="blue">timely basis</font>, if at all</td>
    </tr>
    <tr>
      <td>An extended     <font color="blue">interruption</font> in the supply of our products, including the supply of our     <font color="blue">influenza vaccine</font> and any other high sales volume product, would have an                                         16       _________________________________________________________________    [70]Table of <font color="blue">Contents       </font>adverse  effect  on our results of <font color="blue">operations</font>, which most likely would     <font color="blue">adversely</font> affect the value of our <font color="blue">common stock</font></td>
    </tr>
    <tr>
      <td>Our expansion through <font color="blue">acquisition</font>s and <font color="blue"><font color="blue">joint ventures</font> involves risks</font></td>
    </tr>
    <tr>
      <td>We have expanded our domestic and international markets in part through     <font color="blue">acquisition</font>s  and  joint  ventures,  and we expect to continue to make     <font color="blue">acquisition</font>s and <font color="blue">enter into <font color="blue">joint ventures</font></font> in the future</td>
    </tr>
    <tr>
      <td>Such <font color="blue">transactions</font>     <font color="blue">involve numerous risks</font>, including <font color="blue">possible adverse effects on</font> our operating     results or the <font color="blue">market price</font> of our <font color="blue">common stock</font></td>
    </tr>
    <tr>
      <td>Some of our <font color="blue">acquisition</font>s     and future <font color="blue">acquisition</font>s may also give rise to an <font color="blue">obligation by us</font> to make     <font color="blue">contingent payments</font> or to satisfy certain repurchase obligations, which     <font color="blue">payments could</font> have an adverse effect on our results of <font color="blue">operations</font></td>
    </tr>
    <tr>
      <td>In     addition, integrating acquired <font color="blue">businesses</font> and <font color="blue">joint ventures</font>:     •   may result in a loss of customers or <font color="blue">product lines</font> of the acquired     <font color="blue">businesses</font> or <font color="blue">joint ventures</font>;     •   requires <font color="blue">significant</font> <font color="blue">management</font> attention; and     •   may place <font color="blue">significant</font> demands on our <font color="blue">operations</font>, information systems and     <font color="blue">financial resources</font></td>
    </tr>
    <tr>
      <td>There  can  be no assurance that our future <font color="blue">acquisition</font>s or joint     <font color="blue">ventures will</font> be successful</td>
    </tr>
    <tr>
      <td>Our ability to continue to <font color="blue">successfully</font> effect     <font color="blue">acquisition</font>s and <font color="blue">joint ventures</font> will depend upon the following:     •   the <font color="blue">availability</font> of suitable <font color="blue">acquisition</font> or <font color="blue">joint venture candidates at</font>     acceptable prices;     •   our ability to consummate such <font color="blue">transactions</font>, which could potentially be     <font color="blue">prohibited due</font> to US or foreign <font color="blue">antitrust</font> <font color="blue">regulations</font>; and     •   the <font color="blue">availability</font> of financing on acceptable terms, in the case of     non-stock <font color="blue">transactions</font></td>
    </tr>
    <tr>
      <td>We <font color="blue">face inherent risk</font> of exposure to <font color="blue">product <font color="blue">liability</font></font> and other claims in     the event that the use of the products we sell results in injury</td>
    </tr>
    <tr>
      <td>Our business involves a risk of <font color="blue">product <font color="blue">liability</font></font> and other claims and     from time to time we are named as a <font color="blue">defendant</font> in cases as a result of our     <font color="blue">distribution</font> of <font color="blue">pharmaceutical</font> and other <font color="blue">healthcare products</font></td>
    </tr>
    <tr>
      <td>Additionally,     we own a <font color="blue">majority interest</font> in a company that <font color="blue">manufacture</font>s dental implants     and we are subject to the <font color="blue">potential risk</font> of <font color="blue">product <font color="blue">liability</font></font> or other     claims relating to the <font color="blue">manufacture</font> of <font color="blue">products by</font> that entity</td>
    </tr>
    <tr>
      <td>One of the     <font color="blue">potential risk</font>s we face in the <font color="blue">distribution</font> of our products is <font color="blue">liability</font>     resulting  <font color="blue">from counterfeit products infiltrating</font> the supply chain</td>
    </tr>
    <tr>
      <td>In     addition, some of the products that we transport and sell are considered     <font color="blue">hazardous materials</font></td>
    </tr>
    <tr>
      <td>The <font color="blue">improper handling</font> of <font color="blue">such materials</font> or <font color="blue">accidents</font>     involving  the  <font color="blue">transportation</font>  of  <font color="blue">such materials</font> could subject us to     <font color="blue">liability</font></td>
    </tr>
    <tr>
      <td>We  have  insurance  policies, including <font color="blue">product <font color="blue">liability</font></font>     insurance,  covering  risks  and in amounts that we consider adequate</td>
    </tr>
    <tr>
      <td>Additionally, in many cases we are covered by <font color="blue">indemnification</font> from the     <font color="blue"><font color="blue">manufacture</font>r</font> of the product</td>
    </tr>
    <tr>
      <td>However, we <font color="blue">cannot provide assurance</font> that the     coverage maintained by us is sufficient to <font color="blue">cover future</font> claims, that it will     be  available  in  adequate  amounts  or at a <font color="blue">reasonable cost</font>, or that     <font color="blue">indemnification</font>  <font color="blue"><font color="blue">agreements</font> will provide adequate protection</font> for us</td>
    </tr>
    <tr>
      <td>A     successful claim <font color="blue">brought against us</font> in excess of <font color="blue">available insurance</font> or     <font color="blue">indemnification</font>, or any claim that results in <font color="blue">significant</font> adverse publicity     against us, could harm our business</td>
    </tr>
    <tr>
      <td>Our <font color="blue">technology</font> segment depends upon continued product development, technical     support and <font color="blue">successful marketing</font></td>
    </tr>
    <tr>
      <td><font color="blue">Competition </font>among companies supplying practice-<font color="blue">management</font> software is     intense and increasing</td>
    </tr>
    <tr>
      <td>Our <font color="blue">future sales</font> of practice-<font color="blue">management</font> software     will <font color="blue">depend on</font>, among other factors:     •   the <font color="blue">effectiveness</font> of our sales and <font color="blue">marketing programs</font>;     •   our ability to enhance our products; and                                         17       _________________________________________________________________    [71]Table of <font color="blue">Contents       </font>•   our ability to <font color="blue">provide ongoing technical support</font></td>
    </tr>
    <tr>
      <td>We  cannot  be sure that we will be successful in introducing and     marketing new software or <font color="blue">software enhancements</font>, or that <font color="blue">such software will</font>     be <font color="blue">released on</font> time or <font color="blue">accepted by</font> the market</td>
    </tr>
    <tr>
      <td>Our <font color="blue">software products</font>, like     <font color="blue">software products</font> generally, may contain undetected errors or bugs when     introduced or <font color="blue">as new versions</font> are released</td>
    </tr>
    <tr>
      <td>Any such     defective software may result in <font color="blue">increased expenses</font> related to the software     and <font color="blue">could <font color="blue">adversely</font> affect</font> our <font color="blue">relationships</font> with the <font color="blue">customers using such</font>     software</td>
    </tr>
    <tr>
      <td>We  do  not have any <font color="blue">patents on</font> our software, and rely upon     copyright, trademark and trade secret laws, as well as contractual and     <font color="blue">common law protections</font></td>
    </tr>
    <tr>
      <td>We <font color="blue">cannot assure</font> you that <font color="blue">such legal protections</font>     will be available or enforceable to protect our <font color="blue">software products</font></td>
    </tr>
    <tr>
      <td>Our <font color="blue">revenues <font color="blue">depend on</font></font> our <font color="blue">relationships</font> with capable sales personnel as     well as key customers, vendors and <font color="blue"><font color="blue"><font color="blue">manufacture</font>r</font>s</font> of the products that we     distribute</td>
    </tr>
    <tr>
      <td>Our  future  operating  results <font color="blue">depend on</font> our ability to maintain     satisfactory <font color="blue">relationships</font> with qualified sales personnel as well as key     customers, vendors and <font color="blue"><font color="blue"><font color="blue">manufacture</font>r</font>s</font></td>
    </tr>
    <tr>
      <td>If we fail to maintain our existing     <font color="blue">relationships</font> with such persons or fail to acquire <font color="blue">relationships</font> with such     <font color="blue">key persons</font> in the future, our business may suffer</td>
    </tr>
    <tr>
      <td>Our <font color="blue">future success</font> is <font color="blue">substantially</font> dependent upon our <font color="blue">senior <font color="blue">management</font></font></td>
    </tr>
    <tr>
      <td>Our <font color="blue">future success</font> is <font color="blue">substantially</font> dependent upon the efforts and     <font color="blue">abilities</font> of members of our existing <font color="blue">senior <font color="blue">management</font></font>, <font color="blue">particularly</font> Stanley     M Bergman, Chairman and Chief Executive Officer, <font color="blue">among others</font></td>
    </tr>
    <tr>
      <td>We have an <font color="blue">employment agreement with</font> Mr</td>
    </tr>
    <tr>
      <td>We do not     currently have “key man” life insurance policies on any of our employees</td>
    </tr>
    <tr>
      <td><font color="blue">Competition </font>for <font color="blue">senior <font color="blue">management</font></font> is intense, and we may not be successful     in attracting and retaining key personnel</td>
    </tr>
    <tr>
      <td><font color="blue">Increases </font>in the cost of shipping or <font color="blue">service trouble with</font> our third-party     <font color="blue"><font color="blue">shippers could</font> harm</font> our business</td>
    </tr>
    <tr>
      <td>Shipping is a <font color="blue">significant</font> expense in the operation of our business</td>
    </tr>
    <tr>
      <td>We     <font color="blue">ship almost</font> all of our US <font color="blue">orders through</font> United Parcel Service, Inc</td>
    </tr>
    <tr>
      <td>Accordingly,  any <font color="blue">significant</font> increase in shipping rates could have an     adverse effect on our operating results</td>
    </tr>
    <tr>
      <td>Similarly, strikes or other service     <font color="blue"><font color="blue">interruption</font>s</font> by those <font color="blue">shippers could</font> cause our operating expenses to rise     and <font color="blue">adversely</font> affect our ability to deliver <font color="blue">products on</font> a <font color="blue">timely basis</font></td>
    </tr>
    <tr>
      <td>We may not be able to respond to <font color="blue">technological</font> change <font color="blue">effectively</font></td>
    </tr>
    <tr>
      <td><font color="blue">Traditional </font><font color="blue">healthcare supply</font> and <font color="blue">distribution</font> <font color="blue">relationships</font> are being     challenged  by  <font color="blue">electronic online commerce solutions</font></td>
    </tr>
    <tr>
      <td>Our <font color="blue">distribution</font>     business is characterized by rapid <font color="blue">technological</font> developments and intense     <font color="blue">competition</font></td>
    </tr>
    <tr>
      <td>The  <font color="blue">advancement</font>  of  <font color="blue">online commerce will</font> require us to     cost-<font color="blue">effectively</font>  adapt  to changing <font color="blue">technologies</font>, to <font color="blue">enhance existing</font>     services and to develop and introduce a variety of <font color="blue">new services</font> to address     changing  demands  of  consumers  and  our  <font color="blue">clients on</font> a <font color="blue">timely basis</font>,     <font color="blue">particularly</font>  in  response  to <font color="blue">competitive</font> offerings</td>
    </tr>
    <tr>
      <td>Our <font color="blue">inability</font> to     anticipate and <font color="blue">effectively</font> respond to changes on a <font color="blue">timely basis</font> could have     an adverse effect on our business</td>
    </tr>
    <tr>
      <td>We are exposed to the risk of an increase in <font color="blue">interest rates</font></td>
    </tr>
    <tr>
      <td>In 2003, we <font color="blue">entered into interest rate swap <font color="blue">agreements</font></font> to exchange our     fixed-rate  interest  rates for variable <font color="blue">interest rates</font> payable on our     dlra230dtta0 million senior notes</td>
    </tr>
    <tr>
      <td>Our fixed <font color="blue">interest rates</font> on the senior notes     were 6dtta94prca and 6dtta66prca for the dlra130dtta0 million and dlra100dtta0 million senior notes,     <font color="blue">respectively</font></td>
    </tr>
    <tr>
      <td>The <font color="blue">variable rate</font> is comprised of LIBOR plus the spreads and     resets on the <font color="blue">interest due dates</font> for the senior notes</td>
    </tr>
    <tr>
      <td>As a result                                         18       _________________________________________________________________    [72]Table of <font color="blue">Contents       </font>of these interest rate swap <font color="blue">agreements</font>, as well as our existing variable     rate  credit  lines,  and loan <font color="blue">agreements</font>, we are exposed to risk from     <font color="blue">fluctuations</font> in <font color="blue">interest rates</font></td>
    </tr>
    <tr>
      <td>Our  <font color="blue">acquisition</font>s may not result in the benefits and <font color="blue">revenue growth</font> we     expect</td>
    </tr>
    <tr>
      <td>We  are in the process of <font color="blue">integrating companies</font> that we acquired,     including the Demedis Group, and <font color="blue">assimilating</font> the <font color="blue">operations</font>, services,     products  and  personnel of each company with our <font color="blue">management</font> policies,     procedures  and strategies</td>
    </tr>
    <tr>
      <td>We cannot be sure that we will achieve the     benefits of <font color="blue">revenue growth</font> that we expect from these <font color="blue">acquisition</font>s or that we     will not incur unforeseen additional costs or expenses in <font color="blue">connection with</font>     these <font color="blue">acquisition</font>s</td>
    </tr>
    <tr>
      <td>To <font color="blue">effectively</font> manage our expected <font color="blue">future growth</font>, we     <font color="blue">must continue</font> to <font color="blue">successfully</font> manage our <font color="blue">integration</font> of these companies and     continue to improve our operational systems, internal procedures, accounts     receivable and <font color="blue">management</font>, financial and <font color="blue">operational controls</font></td>
    </tr>
    <tr>
      <td>If we fail in     any of these areas, our business could be <font color="blue"><font color="blue">adversely</font> affected</font></td>
    </tr>
    <tr>
      <td>The <font color="blue">market price</font> for our <font color="blue">common stock</font> may be <font color="blue">highly volatile</font></td>
    </tr>
    <tr>
      <td>The <font color="blue">market price</font> for our <font color="blue">common stock</font> may be <font color="blue">highly volatile</font></td>
    </tr>
    <tr>
      <td>A variety     of <font color="blue">factors may</font> have a <font color="blue">significant</font> impact on the <font color="blue">market price</font> of our common     stock, including:     •   the <font color="blue">publication</font> of earnings estimates or other research reports and     <font color="blue">speculation</font> in the press or <font color="blue">investment community</font>;     •   changes in our industry and <font color="blue">competitors</font>;     •   our <font color="blue">financial condition</font>, results of <font color="blue">operations</font> and <font color="blue">cash flows</font> and     prospects;     •   any <font color="blue">future issuances</font> of our <font color="blue">common stock</font>, which may include primary     offerings for cash, stock splits, issuances in <font color="blue">connection with</font> business     <font color="blue">acquisition</font>s, restricted stock and the grant or exercise of <font color="blue">stock options</font>     from time to time;     •   the <font color="blue">dilutive impact</font> of <font color="blue">convertible debt on</font> our <font color="blue">earnings per</font> share;     •   <font color="blue">general market</font> and <font color="blue">economic conditions</font>; and     •   any outbreak or <font color="blue">escalation</font> of <font color="blue">hostilities</font> in areas we do business</td>
    </tr>
    <tr>
      <td>In addition, the Nasdaq National Market can experience <font color="blue">extreme price</font>     and volume <font color="blue">fluctuations</font> that can be unrelated or <font color="blue">disproportionate</font> to the     operating performance of the <font color="blue">companies listed on</font> Nasdaq</td>
    </tr>
    <tr>
      <td>Broad market and     industry <font color="blue">factors may</font> <font color="blue">negatively affect</font> the <font color="blue">market price</font> of our <font color="blue">common stock</font>,     <font color="blue">regardless</font> of actual operating performance</td>
    </tr>
    <tr>
      <td>In the past, following periods     of <font color="blue">volatility</font> in the <font color="blue">market price</font> of a company’s securities, securities     class <font color="blue">action <font color="blue">litigation</font></font> has <font color="blue">often been instituted against companies</font></td>
    </tr>
    <tr>
      <td><font color="blue">This     </font>type of <font color="blue">litigation</font>, if instituted, could result in substantial costs and a     diversion of <font color="blue">management</font>’s attention and resources, which would harm our     business</td>
    </tr>
    <tr>
      <td>Certain provisions in our <font color="blue">governing <font color="blue">documents</font></font> and other <font color="blue">documents</font> to which     we are a party may discourage third-party offers to acquire us that might     otherwise result in our <font color="blue">stockholders</font> receiving a <font color="blue">premium over</font> the market     price of their shares</td>
    </tr>
    <tr>
      <td>The provisions of our <font color="blue">certificate</font> of incorporation and by-laws may make     it  more  <font color="blue">difficult</font>  for  a  <font color="blue">third party</font> to acquire us, may discourage     <font color="blue">acquisition</font> bids, and may limit the price that <font color="blue">certain investors might</font> be     willing  to  pay  in  the future for shares of our <font color="blue">common stock</font></td>
    </tr>
    <tr>
      <td><font color="blue">These     </font>provisions, among other things:     •   require the <font color="blue">affirmative vote</font> of the holders of at least 60prca of the     shares of <font color="blue">common stock</font> entitled to vote to approve a merger, <font color="blue">consolidation</font>,     or a sale, lease, transfer or exchange of all or <font color="blue">substantially</font> all of our     assets; and                                         19       _________________________________________________________________    [73]Table of <font color="blue">Contents       </font>•   require the <font color="blue">affirmative vote</font> of the holders of at least 66 2/3prca of our     <font color="blue">common stock</font> entitled to vote to:       •   remove a director; and         •   to amend or repeal our by-laws, with certain limited <font color="blue">exceptions</font></td>
    </tr>
    <tr>
      <td>In addition, our 1994 Stock Incentive Plan, 1996 Non-Employee Director     <font color="blue">Stock Incentive Plan </font>and 2001 Non-Employee Director Incentive Plan provide     for <font color="blue">accelerated vesting</font> of <font color="blue">stock options</font> upon a change in control, and     certain  <font color="blue">agreements</font>  <font color="blue">between us</font> and our <font color="blue">executive officers</font> provide for     <font color="blue">increased severance payments</font> if those <font color="blue">executive officers</font> are terminated     without cause <font color="blue">within two years</font> after a change in control</td>
    </tr>
    <tr>
      <td>We  also  have  a <font color="blue">stockholder rights</font> plan that could make it more     <font color="blue">difficult</font> for a <font color="blue">third party</font> to acquire us if our <font color="blue">Board of Directors </font>does not     determine  that  the  <font color="blue">acquisition</font>  proposal  is  adequate  and  in the     <font color="blue">stockholders</font>’ best interest</td>
    </tr>
    <tr>
      <td>Tax  <font color="blue">legislation</font>  <font color="blue">initiatives</font> <font color="blue">could <font color="blue">adversely</font> affect</font> the Company’s net     earnings and tax li<font color="blue">abilities</font></td>
    </tr>
    <tr>
      <td>We are subject to the tax laws and <font color="blue">regulations</font> of the <font color="blue">United States </font>    federal, state and local <font color="blue">government</font>s, as well as <font color="blue">foreign jurisdictions</font></td>
    </tr>
    <tr>
      <td><font color="blue">From     </font>time to time, <font color="blue">various legislative <font color="blue">initiatives</font> may</font> be proposed that could     <font color="blue">adversely</font> affect our <font color="blue">tax positions</font></td>
    </tr>
    <tr>
      <td>There can be no assurance that our     <font color="blue">effective tax rate will</font> not be <font color="blue"><font color="blue">adversely</font> affected</font> by these <font color="blue">initiatives</font></td>
    </tr>
    <tr>
      <td>In     addition, tax laws and <font color="blue">regulations</font> are <font color="blue">extremely complex</font> and subject to     varying  <font color="blue">interpretations</font></td>
    </tr>
    <tr>
      <td>Although we believe that our <font color="blue">historical tax</font>     positions are sound and consistent with <font color="blue">applicable laws</font>, <font color="blue">regulations</font> and     existing precedent, there can be no assurance that our <font color="blue">tax positions</font> will     not be <font color="blue">challenged by relevant tax authorities</font> or that we would be successful     in any <font color="blue">such challenge</font></td>
    </tr>
  </tbody>
</table>